Krystal Biotech (FRA:4KB) FFO


FRA:4KB Krystal Biotech Inc FRA:4KB
58 GF Score
Price €303.60
GF Value €263.13
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech FFO?

FFO (Funds from operations) only applies to REITs.

FRA:4KB
58GF Score
Krystal Biotech Inc FRA:4KB
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €303.60 is trading 15.4% above its estimated GF Value™ of €263.13. GuruFocus considers Krystal Biotech to be Modestly Overvalued.

Key valuation signals for FRA:4KB:

  • FFO:
  • GF Value™: €263.13 vs. price of €303.60 (15.4% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score

Get the complete analysis for FRA:4KB

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€303.60
Price
€263.13
GF Value